Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.4M Buy
547,500
+329,600
+151% +$8.78M 0.04% 434
2025
Q4
$5.42M Sell
217,900
-38,000
-15% -$958K 0.02% 746
2025
Q3
$6.52M Buy
255,900
+208,100
+435% +$5.14M 0.02% 556
2025
Q2
$1.16M Buy
+47,800
New +$1.11M 0.01% 1198
2024
Q4
Sell
-26,300
Closed -$761K 3030
2024
Q3
$761K Buy
+26,300
New +$767K ﹤0.01% 1386
2023
Q1
Sell
-11,000
Closed -$563K 3022
2022
Q4
$563K Buy
+11,000
New +$527K 0.01% 1330
2022
Q2
Sell
-41,000
Closed -$2.12M 3536
2022
Q1
$2.12M Buy
+41,000
New +$2.13M 0.02% 618

Other funds holding PFE

HRT Financial's PFE Position: Q1 2026 in Review

HRT Financial sold out of Pfizer (PFE) in Q1 2026, closing a stake of 664,987 shares — an estimated $17.7M sold.

HRT Financial first reported a position in PFE in Q4 2014 and held it in 25 quarters. The position peaked at $139M in Q1 2025. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • HRT Financial reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 664,987 Pfizer shares in Q1 2026, an estimated $17.7M.
  • HRT Financial first reported a position in Pfizer in Q4 2014 and held it in 25 quarters.
  • HRT Financial's Pfizer position peaked at $139M in Q1 2025.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.